Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : ASK: "THE LAST DON" OF MOMENTUM TRADES -- Ignore unavailable to you. Want to Upgrade?

To: Cheesehead who wrote (12612)	4/29/1999 8:20:00 AM
From: Jacalyn Deaner	Read Replies (1) \| Respond to of 15987

ENDV - biomedical breakthrough - floor at .50, three and more patents in premarket now and acceptance is huge: Wednesday April 28, 5:44 pm Eastern Time Company Press Release Endovasc Ltd. Inc. Announces Confirming Evidence on PGE-1 in Preventing Heart Vessel Blockage Presented at Washington DC Meeting MONTGOMERY, Texas--(BUSINESS WIRE)--April 28, 1999--Endovasc Ltd. Inc. (OTC BB:ENDV - news) today announced that Baylor College of Medicine presented new data at the Experimental Biology Meeting last week on the efficacy of Prostaglandin E-1 in inhibiting the migration of vascular smooth muscle cell (thought to be the main cause of reblockage of blood vessels) by disruption of stress fibers and adhesion plaques. Prof. Charles Seidel's (Baylor's Section of Medicine - Cardiovascular Sciences) data was further substantiated by Buerke and co-workers from Johannes Gutenberg-University in Mainz, Germany. Their independent work confirmed (at the same meeting) that Lipo-PGE-1 significantly reduced intima proliferation and smooth muscle cell proliferation in the animal model. ''What this means,'' said company spokesman Dr. David P. Summers, ''is that if this effect continues to be maintained in the human model, then we have a home run product within a $2 billion market. We should have early indications of its success in humans by the beginning of the third quarter. If approval comes from the FDA quickly, we could easily niche out $200 million from this market by the end of three years.'' About the company Endovasc Ltd. Inc. is a biopharmaceutical company using liposomal drug delivery for products that have already shown safety and efficacy in the generic form. The company's products and processes are covered by patents and trade secrets for competing in a $2 billion market. The foregoing statements are made under the ''Safe Harbor'' Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. Contact: PMR & Associates, Encinitas Phone: 760/635-8695 E-mail: pmrandco@aol.com